Biotechnology
Haier Biomedical Presents Digital Blood Management Platform at ISBT Congress 2026, Advancing Its Transition from Equipment Provider to Full-Process Solution Partner
Driving Digital Transformation in Blood Management for Plasma Collection
Centers, Hospitals, and Blood Bank Centers
KUALA LUMPUR, Malaysia, July 21, 2026 /PRNewswire/ -- Haier Biomedical
2026-07-21 14:29
3366
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...
2026-07-21 12:00
2328
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...
2026-07-21 11:50
2641
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] * Group revenue of US...
2026-07-21 06:52
5047
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire...
2026-07-21 05:00
3019
Generative Bionics Introduces Gene.01, a Fully Functional Smart-Skin Humanoid Robot Platform Designed for Safe Human Collaboration
Built in six months, Gene.01 senses touch, proximity, force, and temperature, and it is released with its open-sourced robot model that gives Physical AI developers a shared starting point to build industrial applications Key Highlights * Fastest-ever transition to a functional humanoid: Gene....
2026-07-20 20:00
3874
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
* DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 * Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...
2026-07-20 16:20
3078
Medtrum Advances 300U Tubeless Patch Pump Toward German Launch
Higher-capacity option expands the TouchCare Nano System and supports Medtrum's continued growth in Europe BERLIN, July 20, 2026 /PRNewswire/ -- Medtrum, a global diabetes technology company, today announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, fo...
2026-07-20 15:05
1857
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-07-20 15:00
2549
Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...
2026-07-20 13:47
1993
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combi...
2026-07-20 13:32
2646
Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...
2026-07-20 12:52
2533
Neuronata-R retains conditional approval in South Korea
South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea w...
2026-07-20 07:00
2081
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
* Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion. * Strong transaction support, with a unanimous ...
2026-07-20 06:43
4105
NYSE Content Update: AdvanCell Raises $315 Million to Fight Prostate Cancer
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 17, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...
2026-07-17 20:56
7177
Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ -- "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive ...
2026-07-17 14:45
2947
Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform
Targets Japan and Singapore as Part of Broader Asia Expansion TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstream regenerative medicine materials, proces...
2026-07-17 14:12
3498
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
* 250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far * Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 * Completion of rec...
2026-07-17 11:48
6618
The HKIC Presents Stellar Annual Report and Joins Hands with Beyond Ventures to Support World-Class Ophthalmic Healthcare Flagship Projects
"Patient Capital" Nurtures Life Science Innovations: MingMed and Super Vision Featured as Selected Investment Stories in the HKIC's Annual Report HONG KONG, July 17, 2026 /PRNewswire/ -- Beyond Ventures, a Hong Kong-based venture capital firm, warmly congratulates the Hong Kong Investment Corpora...
2026-07-17 09:14
4740
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. * The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix...
2026-07-17 06:00
4508
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 295 media titles]
2026-08-13 23:42Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
16624
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
16398